Intravenous administration of BCG in mice promotes natural killer and T cell-mediated antitumor immunity in the lung.

Autor: Moreo, Eduardo, Jarit-Cabanillas, Aitor, Robles-Vera, Iñaki, Uranga, Santiago, Guerrero, Claudia, Gómez, Ana Belén, Mata-Martínez, Pablo, Minute, Luna, Araujo-Voces, Miguel, Felgueres, María José, Esteso, Gloria, Uranga-Murillo, Iratxe, Arias, Maykel, Pardo, Julián, Martín, Carlos, Valés-Gómez, Mar, del Fresno, Carlos, Sancho, David, Aguiló, Nacho

Publikováno v: Nature Communications; 10/4/2023, Vol. 14 Issue 1, p1-17, 17p

BCG-activation of leukocytes is sufficient for the generation of donor-independent innate anti-tumor NK and γδ T-cells that can be further expanded in vitro.

Autor: Esteso, Gloria, Felgueres, María José, García-Jiménez, Álvaro F., Reyburn-Valés, Christina, Benguría, Alberto, Vázquez, Enrique, Reyburn, Hugh T., Aguiló, Nacho, Martín, Carlos, Puentes, Eugenia, Murillo, Ingrid, Rodríguez, Esteban, Valés-Gómez, Mar

Publikováno v: OncoImmunology; 2023, Vol. 12 Issue 1, p1-16, 16p

BCG-activation of leukocytes is sufficient for the generation of donor-independent innate anti-tumor NK and γδ T-cells that can be further expanded in vitro .

Autor: Esteso G; Department of Immunology and Oncology, National Centre for Biotechnology, Spanish National Research Council, Madrid, Spain., Felgueres MJ; Department of Immunology and Oncology, National Centre for Biotechnology, Spanish National Research Council, Madrid, Spain., García-Jiménez ÁF; Department of Immunology and Oncology, National Centre for Biotechnology, Spanish National Research Council, Madrid, Spain., Reyburn-Valés C; Department of Immunology and Oncology, National Centre for Biotechnology, Spanish National Research Council, Madrid, Spain., Benguría A; Servicio de Genómica, Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain., Vázquez E; Servicio de Genómica, Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain., Reyburn HT; Department of Immunology and Oncology, National Centre for Biotechnology, Spanish National Research Council, Madrid, Spain., Aguiló N; Grupo de Genética de Micobacterias, Departamento de Microbiología y Medicina Preventiva, Facultad de Medicina, Universidad de Zaragoza, IIS-Aragon; Zaragoza, Spain and CIBER Enfermedades Respiratorias, Instituto de Salud Carlos III; Madrid, Spain., Martín C; Grupo de Genética de Micobacterias, Departamento de Microbiología y Medicina Preventiva, Facultad de Medicina, Universidad de Zaragoza, IIS-Aragon; Zaragoza, Spain and CIBER Enfermedades Respiratorias, Instituto de Salud Carlos III; Madrid, Spain.; Servicio de Microbiología, Hospital Universitario Miguel Servet, IIS Aragon; Zaragoza, Spain., Puentes E; Clinical Research Department y Research & Development Department, Biofabri, Grupo Zendal, O'Porriño, Pontevedra, Spain., Murillo I; Clinical Research Department y Research & Development Department, Biofabri, Grupo Zendal, O'Porriño, Pontevedra, Spain., Rodríguez E; Clinical Research Department y Research & Development Department, Biofabri, Grupo Zendal, O'Porriño, Pontevedra, Spain., Valés-Gómez M; Department of Immunology and Oncology, National Centre for Biotechnology, Spanish National Research Council, Madrid, Spain.

Publikováno v: Oncoimmunology [Oncoimmunology] 2022 Dec 22; Vol. 12 (1), pp. 2160094. Date of Electronic Publication: 2022 Dec 22 (Print Publication: 2023).